All posts

AgTech stock Deveron has a 193 per cent upside, says Roth Capital

Roth Capital Partners likes the news coming from Canadian AgTech stock Deveron Corp (Deveron Stock Quote, Charts, News, Analysts, Financials TSXV:FARM), with the company just announcing a new strategic cost optimization plan. In a Flash Note to clients on Thursday, Roth analyst Brian Wright reiterated a “Buy” rating on Deveron, saying that trimming some fat after a couple of years of acquisitions make good sense.

Deveron, which offers data acquisition and analytics services including data analysis for farm inputs and soil testing for the North American market, announced the cost optimization program on Thursday, saying it plans on focusing its efforts on the North American soil testing market as well as synergies coming from recent acquisitions.

“Over the last 24 months, we have acquired ten companies with various skill sets and regional presences,” said David MacMillan, President and CEO, in a press release. “We are realigning our strategy to focus on owning the end-to-end soil testing market. By creating a digitally enabled and unique user experience, we can offer our customers the best solution to providing reliable and independent soil analysis. This renewed focus on integrating the businesses will positively impact our 2023 financial performance.”

Looking at the news, Wright said the selective headcount reductions are focused primarily on engineering, product researchers and some middle management layers, with likely about $3 million in annualized cost savings and a resulting flow to the company’s bottom line. 

Wright said the reductions won’t impact customer couching aspects of Deveron’s business.

“It’s important to note that headcount reductions will not impact any customer couching aspects of the business. All R&D activities are to be focused on increasing collection volume productivity and soil sampling throughput metrics and thus drive growth and profitability enhancements,” Wright said.

“We view the decision as prudent for a number of reasons. First, it signals that the team is focused on profitable growth. Second, management is prioritizing its resources on functions that are customer facing and that drive growth. Lastly, leaner organizations more effectively row in sync,” he said.

On the path ahead, Wright thinks Deveron will finish 2022 with $27.2 million in revenue compared to $8.6 million in 2021 and moving to $43.0 million for 2023. On EBITDA, he is calling for negative $5.4 million in 2022 and moving to positive $5.3 million in 2023. Deveron’s EPS is forecasted to go from negative $0.07 per share in 2021 to negative $0.13 per share in 2022 and to negative $0.06 per share in 2023. 

With his “Buy” rating, Wright reiterated a $1.20 target price, representing at press time a projected one-year return of 193 per cent.

Tagged with: farm
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Walmart is dramatically separating itself from brick and mortar, analyst says

Roth Capital Markets analyst Bill Kirk says Walmart’s (Walmart Stock Quote, Chart, News, Analysts, Financials NYSE:WMT) third-quarter results delivered a… [Read More]

24 minutes ago

Decibel Cannabis. Buy, Sell or Hold?

Haywood Capital Markets analyst Neal Gilmer says the temporary halt of Canadian cannabis imports into Germany is creating near-term pressure… [Read More]

21 hours ago

Lululemn faces an uphill battle, this analyst says

Citigroup analyst Paul Lejuez says Lululemon Athletica (LuLulemon Stock Quote, Chart, News, Analysts, Financials NASDAQ:LULU) is facing a difficult activewear… [Read More]

23 hours ago

Xtract One Technologies CFO Karen Hersh talks to Cantech Letter

Xtract One Technologies (Xtract One Technologies Stock Quote, Chart, News, Analysts, Financials TSX:XTRA) CFO Karen Hersh says the company’s frictionless… [Read More]

1 day ago

Rocket Doctor CEO, Dr. Essam Hamza, talks to Cantech Letter

Rocket Doctor (Rocket Doctor Stock Quote, Chart, News, Analysts, Financials CSE:AIDR) CEO Dr. Essam Hamza says the company’s AI-driven clinical… [Read More]

1 day ago

Analyst: Here’s why Target is failing

Roth Capital Markets analyst Bill Kirk maintained his “Neutral” rating and US $90.00 target price on Target Corporation (Target Corporation… [Read More]

2 days ago